Clinical Trials Browser

Phase 2 × Non-Small Cell Lung Cancer NSCLC × Clear all

NCT02879617 2024-01-05

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Phase 2 Completed

47 enrolled 34 charts

Non-Small Cell Lung Cancer NSCLC